FibroGen, Inc. Reports Data from Phase 2 Study of FG-4592 Hemoglobin Correction and Maintenance in End-Stage Renal Patients  
11/5/2012 9:58:21 AM

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced that data from an ongoing Phase 2 study of FG-4592, an orally delivered, small molecule treatment for anemia, were presented on 2 November 2012, at the American Society of Nephrology (ASN) Kidney Week 2012 in San Diego, California. The study was designed to compare FG-4592 , an investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), with an active comparator (epoetin a) in patients with end-stage renal disease (ESRD) receiving hemodialysis, whose hemoglobin (Hb) levels were previously maintained with intravenous (IV) epoetin a and IV iron supplementation.